Cytodyn Inc (CYDY)

[ohm20]

Leronlimab blocks a valid target for virus entry into the cells. Can a virus hit a different target to bypass this - that is the question?? Welcome educated responses.

Leronlimab doesn't block the virus. The virus uses the Ace2 receptor not the CCR5 receptor. Leronlimab blocks cytokines which results in reducing inflammatory macrophages and a boosting natural killer t-cells that attack viruses.

Leronlimab at a minimum will be approved for Graft vs Host disease.

Might get approval for cancer but I doubt a game changer.

Approval in HIV, GVHD, definitely cancer, 47 different diseases that it has a very high likelihood of working for.